艾美疫苗拟配售1550万股新H股 预计募资约7770万元
2月28日，艾美疫苗（06660）发布公告，宣布与配售代理签订配售协议，计划按每股5.01港元的价格配售1550万股新H股。该配售股份相当于公告日期现有已发行H股股份数目的约3.15%及现有已发行股份数目的约1.28%。假设所有配售股份顺利配售，预计配售事项所得款项总额约为7770万元，扣除相关成本后的净额约为7470万元，净发行价约为每股4.82港元。
此次配售价格较2025年2月27日的收市价6.26港元折让约19.97%，较截至2025年2月26日的五个交易日平均收市价5.88港元折让约14.8%。本公司预计配售所得款项将用于加速多个产品线的研发、市场营销及营运资金等用途。由于配售股份将根据股东于2024年5月20日的特别决议案授予董事会的一般授权配发，故本公司无需获得股东批准。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10